Anti-cancer oligodeoxynucleotides
AssigneesServices, The United States of America, as represented by the Secretary, Department of Health and Human
InventorsDennis M. Klinman, Hidekazu Ikeuchi
Life of this patent
Estimating the term…
Abstract
It is disclosed herein that suppressive OD Ns are of use for preventing or delaying the formation of a tumor, reducing the risk of developing a tumor, treating a tumor, preventing conversion of a benign to a malignant lesion, or preventing metastasis. In some embodiments, methods are disclosed herein for treating, preventing or reducing the risk of developing a tumor, such as esophageal, gastrointestinal, liver, lung, skin and colon tumors or a mesothelioma. Generally, the methods disclosed herein include selecting a subject for treatment and administering to the subject a therapeutically effective amount of one or more suppressive ODN. In some examples, additional agents can also be administered to the subject of interest.
Claims20
A method for treating, preventing or delaying development of a tumor in a subject, comprising
- selecting a subject with a tumor or at risk for developing a tumor, and
- administering to the subject a therapeutically effective amount of a suppressive oligodeoxynucleotide effective to inhibit inflammation, wherein the suppressive oligodeoxynucleotide is at least about 8 nucleotides in length, forms a G-tetrad, has a CD value of greater than about 2.9, and comprises at least four guanosines,
- thereby treating, preventing or delaying development of the tumor in the subject.
A method of reducing the risk of a subject to developing a tumor, comprising
- selecting a subject who has been exposed to a carcinogen;
- and
- administering to the subject a therapeutically amount of a suppressive oligodeoxynucleotide effective to inhibit inflammation, wherein the suppressive oligodeoxynucleotide is at least about 8 nucleotides in length, forms a G-tetrad, has a CD value of greater than about 2.9, and comprises at least four guanosines,
- thereby reducing the risk of the subject to developing the tumor.
Dependencies are inferred from the claim text.